Quantum Pharma surges as subsidiary signs out-licensing deal

Quantum Pharma shares surged on Monday after it said its subsidiary Colonis Pharma has signed an out-licensing deal with a major German pharmaceutical group.

The Kent-based group has granted its new partner exclusive licence to secure the marketing authorisation required to use Colonis’ Aviticol treatment in Germany, Quantum said, indicating the deal will be worth £1.11m.

The London-listed company added the German firm will also receive the exclusive right to commercialise, manufacture, sell and distribute the product in the country.

“This type of out-licensing deal forms an integral part of our business plan and model for niche pharmaceuticals through our Colonis and Lamda divisions,” said Quantum’s chief executive Andrew Scaife.

"This is a significant out-licence into a major healthcare market which provides a base for further out-licences and product launches.”

Quantum shares were up 22.37% to 0.930p at 1059 BST on Monday.